PSCI has conducted a materiality review for the sector every few years (2013, 2017, 2020). We are pleased to publish our latest assessment, this time applying a double materiality framework. The assessment is specifically focused on supply chains for the Pharmaceutical & Healthcare industries, and takes into account member views and a range of outside sources.

“New regulations and investor demands are raising the bar for company reporting on supply chain responsibility. This year's assessment highlights the growing importance of robust supply chain programs, encompassing a wider range of issues. It also reflects the changing nature of the industry’s products and markets, with biosafety joining the list for the first time and the issue of substandard and falsified medicines gaining prominence. Tackling climate change remains essential, as does responsible business practice against bribery and corruption. The PSCI Board uses this assessment as a control point to guide its own strategy. It can be a valuable resource for member companies comparing their own assessments and for those outside the sector to understand how supply chain risks are viewed within the industry. I hope you find it useful.” Dr. Deirdre O’Reilly Global EH&S Supplier Operations and Business Development Lead, Viatris & PSCI Chair

We encourage members, suppliers and our other stakeholders and invited to read the report and use it as an input to their own planning processes.

For anyone with comments to the report, please contact Rosie.Towe@Carnstone.com.

We're delighted to announce that Caroline O'Brien, Global Quality Audit - Hub Director Asia Pacific at AstraZeneca & former PSCI Chair, will be speaking at CPHI Japan on 17 April.

Japan is the world's third largest pharmaceutical market, with a share of 7% of the global market. Hosted this year in Tokyo, CPHI Japan facilitates opportunities for local and international companies to develop meaningful connections and grow their business in the heart of pharma in Japan.

Caroline will present on how the PSCI's Audit tools and sharing platform put ESG into practice and build responsible supply chains. You can find out more about her session here and register to attend CPHI Japan here.

PHARMAP 2024 is a B2B networking event that brings together over 330 pharmaceutical professionals from various sectors of the industry's value chain. From pharmaceutical companies to contract manufacturing organisations, service providers, and other experts in pharmaceutical manufacturing and packaging, this gathering is a unique opportunity to connect and collaborate with like-minded professionals.

At the event, attendees from Merck, Bayer, Sanofi, GSK and other pharma leaders share their experiences, present their case studies, and discuss the latest industry trends and innovations. Whether you're looking to develop new partnerships, expand your knowledge, or simply network with industry peers, PHARMAP 2024 is the platform to achieve your goals.

Enric Bosch, PSCI Treasurer, will be speaking at the event about our approach to responsible supply chain management. Please see the event agenda for further information and if you are attending, do stop by and say hello.

WE ARE PLEASED TO ANNOUNCE THAT DEIRDRE O’REILLY HAS BEEN APPOINTED CHAIR OF THE PHARMACEUTICAL SUPPLY CHAIN INITIATIVE (PSCI).

She succeeds Ingrid Vande Velde who completed her Chairmanship at the end of 2023 and will transition into the role of Past Chair. The Board also welcomed Robert Williams as Vice Chair.

As Senior Director of Global EHS Supplier Operations and Business Development at Viatris, Deirdre safeguards Viatris’ supply chain by minimizing risk from a business continuity, liability, and reputational perspective.

Deirdre brings over 24 years of experience in the pharmaceutical industry to her new role within the PSCI. She has held leadership positions in site operations, EHS, supply chain, and technical product transfers at Pfizer, Upjohn Pfizer, and today with Viatris. She is a passionate advocate for responsible practices in the pharmaceutical supply chain and committed to working with the PSCI to achieve its strategic vision for excellence in patient, safety, environmental, and social outcomes.

Deirdre has been a longstanding and actively engaged member of the PSCI, holding a range of roles on both Committees and specialist Topic teams, such as Decarbonization and Human Rights & Labor. As Chair of the Governance Committee, Deirdre worked to expand the scope and impact of the committee, enabling the formation of the Partnerships Committee, launch of the Member Engagement survey & Mentoring program, and supplier impact workstream.

In her role as Chair, Deirdre will lead the Board in the delivery of the PSCI’s strategic vision for excellence in safety, environmental, and social outcomes across the global pharmaceutical and healthcare value chain. She will also work to strengthen the PSCI's relationships with its members and other stakeholders.

Speaking about her appointment Deirdre says,

I am honored to be Chair of the PSCI and to be a part of this organization at these exciting and influential times. Our launch this year of the new supplier partnership model and Projects Committee are two major initiatives that I believe will change the shape and direction of the PSCI, enhance our recognition, and make us more synonymous with responsible practices in the supply chain.

I firmly believe that collectively, as One Voice, we are impactful and can make a difference in the delivery of responsible practices across the pharmaceutical supply chain. I look forward to working with everyone on the delivery of our shared strategy.